Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Mar 10, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 09, 2023

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Mar 06, 2023

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET

Feb 24, 2023

Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

Feb 10, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 08, 2023

Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference

Jan 17, 2023

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Jan 17, 2023

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

Jan 13, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 04, 2023

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 11

Investor Tools

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact